Search

Displaying 1 - 25 of 596 items.

Pages

“Perspectives on the Properties of Stem Cells” (2005), by Ernest McCulloch and James Till

In 2005, Ernest McCulloch and James Till published the article “Perspectives on the Properties of Stem Cells,” which discusses the various properties and future possibilities for the use of stem cells. Stem cells are unspecialized cells that can develop into several different cell types. In the article published in the journal Nature on 1 October 2005, the authors say they wrote the article to dispel misconceptions about what stem cells are, what they do, address some controversies surrounding stem cells, and discuss potential uses of stem cells.

Format: Articles

Subject: Publications

"A Stochastic Model of Stem Cell Proliferation, Based on the Growth of Spleen Colony-Forming Cells” (1964) by James Till, Ernest McCulloch, and Louis Siminovitch

In 1964, authors James Till, Ernest McCulloch, and Louis Siminovitch, published A Stochastic Model of Stem Cell Proliferation, Based on The Growth of Spleen Colony-Forming Cells, which discussed possible mechanisms that control stem cell division. The authors wrote the article following their experiments with spleens of irradiated mice to demonstrate the existence of stem cells, had unknown properties.

Format: Articles

Subject: Experiments

Pfeffer Cell Apparatus

The Pfeffer Zelle (Pfeffer Cell Apparatus), invented by Wilhelm Pfeffer in 1877, measured the minimum pressure needed to prevent a pure solvent from passing into a solution across a semi-permeable membrane, called osmotic pressure. The apparatus provided Pfeffer with a way to quantitatively measure osmotic pressure. Pfeffer devised the apparatus in the 1870s at the University of Basel in Basel, Switzerland, and he described the Pfeffer Cell Apparatus in his 1877 book Osmotische Untersuchungen: Studien Zur Zellmechanik (Osmotic Investigations: Studies on Cell Mechanics).

Format: Articles

Subject: Technologies

Hematopoietic Stem Cell Transplantation

The purpose of regenerative medicine, especially tissue engineering, is to replace damaged tissue with new tissue that will allow the body to resume normal function. The uniqueness of tissue engineering is that it can restore normal structure in addition to repairing tissue function, and is often accomplished using stem cells. The first type of tissue engineering using stem cells was hematopoietic stem cell transplantation (HSCT), a surgical procedure in which hematopoietic stem cells (HSCs) are infused into a host to treat a variety of blood diseases, cancers, and immunodeficiencies.

Format: Articles

Subject: Technologies

Hematopoietic Stem Cells

The discovery of hematopoietic stem cells (HSCs) provided a pioneering step in stem cell research. HSCs are a type of multipotent adult stem cell, characterized by their ability to self-renew and differentiate into erythrocyte (red blood cell) and leukocyte (white blood cell) cell lineages. In terms of function, these cells are responsible for the continual renewal of the erythrocytes, leukocytes, and platelets in the body through a process called hematopoiesis. They also play an important role in the formation of vital organs such as the liver and spleen during fetal development.

Format: Articles

Subject: Processes

Edward Donnall Thomas (1920-2012)

Edward Donnall Thomas, an American physician and scientist, gained recognition in the scientific community for conducting the first bone marrow transplant, a pioneering form of hematopoietic stem cell transplantation (HSCT). Bone marrow transplants are considered to be the first successful example of tissue engineering, a field within regenerative medicine that uses hematopoietic stem cells (HSCs) as a vehicle for treatment. Prior to Thomas's groundbreaking work, most blood-borne diseases, including certain inherited and autoimmune diseases, were considered lethal.

Format: Articles

Subject: People

Cord Blood Banking

Cord blood banks are institutions designed to store umbilical cord blood (UCB) stem cells. UCB, a source of hematopoietic stem cells (HSCs), has garnered attention from scientific and medical communities since its first successful use in a hematopoietic stem cell transplant (HSCT) in 1988. The umbilical cord is the lifeline by which the growing fetus is nourished by the mother. Once regarded as medical waste, the umbilical cord has become a source of lifesaving treatment.

Format: Articles

Subject: Technologies, Reproduction

HeLa Cell Line

The HeLa cell line was the first immortal human cell line that George Otto Gey, Margaret Gey, and Mary Kucibek first isolated from Henrietta Lacks and developed at The Johns Hopkins Hospital in Baltimore, Maryland, in 1951. An immortal human cell line is a cluster of cells that continuously multiply on their own outside of the human from which they originated. Scientists use immortal human cell lines in their research to investigate how cells function in humans.

Format: Articles

Subject: Technologies, Experiments, People, Ethics

Stem Cells

According to the US National Institutes of Health (NIH), the standard American source on stem cell research, three characteristics of stem cells differentiate them from other cell types: (1) they are unspecialized cells that (2) divide for long periods, renewing themselves and (3) can give rise to specialized cells, such as muscle and skin cells, under particular physiological and experimental conditions. When allowed to grow in particular environments, stem cells divide many times. This ability to proliferate can yield millions of stem cells over several months.

Format: Articles

Subject: Processes

Umbilical Cord Blood Stem Cells (UCBSC)

Umbilical cord blood (UCB) stem cells are hematopoietic stem cells (HSC) that are recovered from the blood of the umbilical cord and placenta after birth. Umbilical cord blood is rich in cells that express the CD34 molecule, a surface protein that identifies cells as stem cells. Prior to the discovery of UCB stem cells, it was standard procedure to discard the umbilical cord and placenta; now much effort is devoted to raising public awareness and to encouraging people to store or donate cord blood.

Format: Articles

Subject: Processes, Reproduction

The First Successful Cloning of a Gaur (2000), by Advanced Cell Technology

The first successful cloning of a gaur in 2000 by Advanced Cell Technology involved the cells of two animals: an egg cell from a domestic cow and a skin cell from a gaur. The researchers extracted the egg cell from the ovary of the domestic cow and the skin cell from the skin of the gaur. First, the researchers performed nuclear transplantation on the egg cell of the cow, during which they removed the nucleus of the egg cell. The mitochondria of the egg cell remained intact inside the cell.

Format: Graphics

Subject: Experiments, Organisms, Reproduction

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells (iPSCs) are cells derived from non-pluripotent cells, such as adult somatic cells, that are genetically manipulated so as to return to an undifferentiated, pluripotent state. Research on iPSCs, initiated by Shinya Yamanaka in 2006 and extended by James Thompson in 2007, has so far revealed the same properties as embryonic stem cells (ESCs), making their discovery potentially very beneficial for scientists and ethicists alike.

Format: Articles

Subject: Technologies

Stem Cell Tourism

When James Thomson of the University of Wisconsin announced in 1998 that he had derived and cultured human embryonic stem cells(hESCs), Americans widely believed-and accepted-that stem cells would one day be the basis of a multitude of regenerative medical techniques. Researchers promised that they would soon be able to cure a variety of diseases and injuries such as cancer, diabetes, Parkinson's, spinal cord injuries, severe burns, and many others. But it wasn't until January 2009 that the Food and Drug Administration approved the first human clinical trials using hESCs.

Format: Articles

Subject: Theories, Ethics

Human Embryonic Stem Cells

Stem cells are undifferentiated cells that are capable of dividing for long periods of time and can give rise to specialized cells under particular conditions. Embryonic stem cells are a particular type of stem cell derived from embryos. According to US National Institutes of Health (NIH), in humans, the term "embryo" applies to a fertilized egg from the beginning of division up to the end of the eighth week of gestation, when the embryo becomes a fetus. Between fertilization and the eighth week of gestation, the embryo undergoes multiple cell divisions.

Format: Articles

Subject: Processes, Reproduction

Ethics and Induced Pluripotent Stem Cells

The recent development of induced pluripotent stem cells (iPSCs) and related technologies has caught the attention of scientists, activists, politicians, and ethicists alike. IPSCs gained immediate international attention for their apparent similarity to embryonic stem cells after their successful creation in 2006 by Shinya Yamanaka and in 2007 by James Thompson and others.

Format: Articles

Subject: Technologies, Ethics

"Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells" (2007), by Junying Yu et al.

On 2 December 2007, Science published a report on creating human induced pluripotent stem (iPS) cells from human somatic cells: "Induced Pluripotent Stem Cell Lines Derived from Human Somatic Cells." This report came from a team of Madison, Wisconsin scientists: Junying Yu, Maxim A. Vodyanik, Kim Smuga-Otto, Jessica Antosiewicz-Bourget, Jennifer L. Frane, Shulan Tian, Jeff Nie, Gudrun A. Jonsdottir, Victor Ruotti, Ron Stewart, Igor I. Slukvin, and James A. Thomson.

Format: Articles

Subject: Publications

"Derivation of Pluripotent Stem Cells from Cultured Human Primordial Germ Cells" (1998), by John Gearhart et al.

In November 1998, two independent reports were published concerning the first isolation of pluripotent human stem cells, one of which was "Derivation of Pluripotent Stem Cells from Cultured Human Primordial Germ Cells." This paper, authored by John D. Gearhart and his research team - Michael J Shamblott, Joyce Axelman, Shunping Wang, Elizabeith M. Bugg, John W. Littlefield, Peter J. Donovan, Paul D. Blumenthal, and George R. Huggins - was published in Proceedings of the National Academy of Science soon after James A.

Format: Articles

Subject: Publications

"Generation of Induced Pluripotent Stem Cells Using Recombinant Proteins" (2009), by Hongyan Zhou et al.

Induced pluripotent stem cells (iPSCs) are studied carefully by scientists not just because they are a potential source of stem cells that circumvents ethical controversy involved with experimentation on human embryos, but also because of their unique potential to advance the field of regenerative medicine. First generated in a lab by Kazutoshi Takahashi and Shinya Yamanaka in 2006, iPSCs have the ability to differentiate into cells of all types.

Format: Articles

Subject: Publications

Nightlight Christian Adoptions, et al. v. Thompson, et al. (2001)

Nightlight Christian Adoptions et al. v. Thompson et al. was a lawsuit filed in the United States District Court for the District of Columbia on 8 March 2001. The suit was filed because Nightlight Christian Adoptions, a frozen embryo adoption agency, felt that the Guidelines for Research Using Human Pluripotent Stem Cells published by the National Institutes for Health were unlawful and violated the restrictions on human embryo research put into place by the Dickey-Wicker Amendment. Additional plaintiffs with this suit were the Christian Medical Association, adult stem cell researcher Dr.

Format: Articles

Subject: Legal, Reproduction

Robert Alan Good (1922-2003)

Robert Alan Good was an American physician and scientific researcher who explored the cellular mechanisms of immunity. His research and discoveries earned him the label of "father of modern immunology." Though his work in immunology is considered his greatest scientific achievement, Good is also well known for his work with tissue engineering. From his research on immunology, Good was able to perform the first successful allogeneic (donor and recipient are unrelated) bone marrow transplant.

Format: Articles

Subject: People

Thomson, et al. v. Thompson, et al. (2001)

Thomson, et al. v. Thompson, et al. was a lawsuit filed in the United States District Court for the District of Columbia on 8 May 2001 as Civil Action Number 01-CV-0973. This lawsuit was filed in hopes of gaining injunctive relief against a moratorium on the federal funding of stem cell research. The plaintiffs in the case were seven prominent scientists who performed embryonic stem cell research and three patients: James Thomson, Roger Pedersen, John Gearhart, Douglas Melton, Dan Kaufman, Alan Trounson, Martin Pera, Christopher Reeve, James Cordy, and James Tyree.

Format: Articles

Subject: Legal

Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. (ACT) is a biotechnology company that uses stem cell technology to develop novel therapies in the field of regenerative medicine. Formed in 1994, ACT grew from a small agricultural cloning research facility located in Worcester, Massachusetts, into a multi-locational corporation involved in using both human embryonic stem cells (hESC) and human adult stem cells as well as animal cells for therapeutic innovations.

Format: Articles

Subject: Organizations, Reproduction

"Embryonic Stem Cell Lines Derived from Human Blastocytes" (1998), by James Thomson

After becoming chief pathologist at the University of Wisconsin-Madison Wisconsin Regional Primate Center in 1995, James A. Thomson began his pioneering work in deriving embryonic stem cells from isolated embryos. That same year, Thomson published his first paper, "Isolation of a Primate Embryonic Stem Cell Line," in Proceedings of the National Academy of Sciences of the United States of America, detailing the first derivation of primate embryonic stem cells. In the following years, Thomson and his team of scientists - Joseph Itskovitz-Eldor, Sander S. Shapiro, Michelle A.

Format: Articles

Subject: Experiments, Publications

President George W. Bush's Announcement on Stem Cells, 9 August 2001

On 9 August 2001, US President George W. Bush gave an eleven-minute speech from his ranch in Crawford, Texas, on the ethics and fate of federal funding for stem cell research. Bush also announced the creation of a special council to oversee stem cell research. In the speech President Bush acknowledged the importance of issues surrounding stem cell research to many Americans, presented different arguments in favor of and opposing embryonic stem cell research, and explained his decision to limit but not completely eliminate potential federal funding for embryonic stem cell (ESC) research.

Format: Articles

Subject: Legal

"Generation of Germline-Competent Induced Pluripotent Stem Cells" (2007), by Keisuke Okita, Tomoko Ichisaka, and Shinya Yamanaka

In the July 2007 issue of Nature, Keisuke Okita, Tomoko Ichisaka, and Shinya Yamanaka added to the new work on induced pluripotent stem cells (iPSCs) with their "Generation of Germline-Competent Induced Pluripotent Stem Cells" (henceforth abbreviated "Generation"). The authors begin the paper by noting their desire to find a method for inducing somatic cells of patients to return to a pluripotent state, a state from which the cell can differentiate into any type of tissue but cannot form an entire organism.

Format: Articles

Subject: Publications

Pages